Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.136
Buy
RSI(14)
54.897
Neutral
STOCH(KDJ)(9,3,3)
64.227
Neutral
ATR(14)
0.449
Low Volatility
CCI(14)
49.931
Neutral
Williams %R
43.750
Buy
TRIX(12,20)
0.753
Sell
StochRSI(14)
0.000
Sell
Search
ASP Isotopes Inc
ASPIAdd to Watchlist
5.800USD
-0.290-4.76%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
730.24MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of ASP Isotopes Inc
Currency: USD Updated: 2026-05-15Key Insights
ASP Isotopes Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 44 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ASP Isotopes Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
ASP Isotopes Inc Highlights
StrengthsRisks
ASP Isotopes Inc. is a development stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100, and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 5407.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 23.85M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 23.85M.
Overvalued
The company’s latest PE is -2.75, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 73.95M shares, increasing 13.33% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 132.94K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
13.000
Target Price
+113.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of ASP Isotopes Inc is 8.55, ranking 49 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 16.66M, representing a year-over-year increase of 1295.41%, while its net profit experienced a year-over-year increase of 757.27%.
Score
Financials
7.30
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.81
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.66
ASP Isotopes Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of ASP Isotopes Inc is 7.88, ranking 42 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -2.75, which is -58.63% below the recent high of -1.14 and -486.61% above the recent low of -16.13.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 44/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of ASP Isotopes Inc is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 13.00, with a high of 15.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
13.000
Target Price
+113.46%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
ASP Isotopes Inc
ASPI
3
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of ASP Isotopes Inc is 8.99, ranking 27 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 6.57 and the support level at 4.97, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
6.080
Sell
MA10
5.694
Buy
MA20
5.505
Buy
MA50
5.122
Buy
MA100
5.668
Buy
MA200
7.233
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of ASP Isotopes Inc is 5.00, ranking 73 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 58.74%, representing a quarter-over-quarter increase of 41.04%. The largest institutional shareholder is Paul Tudor Jones, holding a total of 132.94K shares, representing 0.11% of shares outstanding, with 46.26% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ASP Isotopes Inc is 2.85, ranking 113 out of 155 in the Pharmaceuticals industry. The company's beta value is 3.28. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
3.25
VaR
--
240-Day Maximum Drawdown
+71.03%
240-Day Volatility
+102.10%
Return
Best Daily Return
60 days
+15.61%
120 days
+16.61%
5 years
--
Worst Daily Return
60 days
-9.74%
120 days
-12.43%
5 years
--
Sharpe Ratio
60 days
+0.70
120 days
-0.04
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+71.03%
3 years
+71.03%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.29
3 years
+3.92
5 years
--
Skewness
240 days
+0.80
3 years
+0.64
5 years
--
Volatility
Realised Volatility
240 days
+102.10%
5 years
--
Standardised True Range
240 days
+12.42%
5 years
--
Downside Risk-Adjusted Return
120 days
-8.67%
240 days
-8.67%
Maximum Daily Upside Volatility
60 days
+86.05%
Maximum Daily Downside Volatility
60 days
+62.97%
Liquidity
Average Turnover Rate
60 days
+5.36%
120 days
+6.21%
5 years
--
Turnover Deviation
20 days
-11.63%
60 days
-1.00%
120 days
+14.62%
Peer Comparison
Pharmaceuticals
ASP Isotopes Inc
ASPI
7.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
